Bailey, Clifford J (2019). FDA guidance on cardiovascular risk of antidiabetic therapies: one decade later. Diabetes, Obesity and Metabolism, 21 (5), pp. 1079-1080.
Abstract
The 2008 FDA guidance for industry on cardiovascular (CV) risk of new antidiabetic therapies arose from a history of CV safety concerns brought to a head by findings with rosiglitazone and the ACCORD trial of intensive glycaemic control.
| Publication DOI: | https://doi.org/10.1111/dom.13669 |
|---|---|
| Divisions: | College of Health & Life Sciences > School of Biosciences College of Health & Life Sciences > School of Biosciences > Cell & Tissue Biomedical Research College of Health & Life Sciences College of Health & Life Sciences > Chronic and Communicable Conditions |
| Additional Information: | This is the peer reviewed version of the following article: Bailey, C. J. (2019), FDA guidance on cardiovascular risk of antidiabetic therapies: one decade later. Diabetes Obes Metab. Accepted Author Manuscript, which has been published in final form at https://doi.org/10.1111/dom.13669. This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving. |
| Uncontrolled Keywords: | Internal Medicine,Endocrinology, Diabetes and Metabolism,Endocrinology |
| Publication ISSN: | 1463-1326 |
| Last Modified: | 22 Aug 2025 07:24 |
| Date Deposited: | 21 Feb 2019 08:28 |
| Full Text Link: | |
| Related URLs: |
http://doi.wile ... .1111/dom.13669
(Publisher URL) http://www.scop ... tnerID=8YFLogxK (Scopus URL) |
PURE Output Type: | Letter |
| Published Date: | 2019-05-01 |
| Published Online Date: | 2019-02-14 |
| Accepted Date: | 2019-02-12 |
| Authors: |
Bailey, Clifford J
(
0000-0002-6998-6811)
|